welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program


Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that it will host a webcast and conference call at 8:00 a.m. Eastern Time (ET) on Monday, March 25, 2019. On the call, Sarepta will provide an update on encouraging 9-month functional and creatine kinase (CK) data from baseline for the 4 patients in the Phase 1 open-label study of Sarepta’s micro-dystrophin gene therapy candidate for Duchenne muscular dystrophy (DMD).  While Sarepta does not intend to provide continuing updates on the patients in its Phase 1 study while it enrolls and conducts its current 24-patient, double-blind, placebo-controlled trial, Sarepta has been informed that its principal investigator recently presented data at a scientific meeting, and believes it appropriate to provide broad access to the data through this webcast and conference call.

Sarepta Therapeutics To Provide Update On Duchenne Muscular Dystrophy Gene Therapy Program